Multiple Sclerosis Society

NICE Appraisal Consultation Document on Teriflunomide for relapsing remitting multiple sclerosis

CONFIDENTIAL NOTE

Further to the public response by the MS Society, I would like to add some additional comments based on the additional information I was sent on a confidential basis as a patient expert.

In the MS Society response there is an assumption that a fairly typical discount for MS patient access schemes of around [redacted] has been applied. That would put teriflunomide broadly into the price spectrum for the range of current first line treatments available through the risk sharing scheme.

[redacted]

[redacted] People with MS would benefit from an additional treatment option, which scores highly on innovation and [redacted]

Yours faithfully,

Nick Rijke

Interim Director of Policy and Research

MS Society

Tel: [redacted]

Email [redacted]